Table 2.

ORs of breast cancer (95% CI) by quartiles of IGF-I (measured by ELISA) and IGFBP-3, and IGF-I/IGFBP-3 molar ratio in the extended study (138 cases of 259 controls)

Quartiles
P trend median*Continuous (log2 scale)
1234
IGF-I DSL ELISA1.001.38 (0.74-2.59)2.23 (1.19-4.16)1.93 (1.00-3.72)0.021.98 (1.12-3.50)
    Adjusted for IGFBP-3 ELISA DSL1.001.28 (0.67-2.47)1.90 (0.91-3.95)1.56 (0.68-3.59)0.231.61 (0.75-3.47)
    Adjusted for Functional IGFBP-31.001.48 (0.78-2.80)2.69 (1.38-5.22)2.43 (1.21-4.90)0.0052.54 (1.37-4.73)
    Number of cases and controls27/7332/6742/5737/62
IGFBP-3 DSL ELISA1.001.53 (0.85-2.77)1.63 (0.91-2.94)2.03 (1.09-3.76)0.022.22 (1.08-4.53)
    Adjusted for IGF-I ELISA DSL1.001.36 (0.73-2.52)1.31 (0.67-2.59)1.49 (0.69-3.23)0.331.47 (0.56-3.87)
    Number of cases and controls26/7435/6336/6341/59
Functional IGFBP-31.000.87 (0.47-1.63)0.59 (0.29-1.18)0.97 (0.44-2.11)0.680.75 (0.46-1.23)
    Adjusted IGF-I ELISA DSL1.000.78 (0.41-1.49)0.43 (0.20-0.93)0.59 (0.24-1.43)0.150.54 (0.31-0.95)
    Number of cases and controls39/6036/6426/7337/62
Molar ratios
    IGF-I ELISA/IGFBP-3 DSL ELISA1.001.07 (0.58-1.96)1.07 (0.58-1.99)1.17 (0.59-2.33)0.681.42 (0.68-2.96)
    Number of cases and controls34/6635/6334/6635/64
    IGF-I ELISA/Functional IGFBP-31.001.00 (0.51-1.96)1.32 (0.65-2.66)2.37 (1.13-5.00)0.022.11 (1.30-3.43)
    Number of cases and controls30/6929/7134/6445/55
  • * Linear trends in ORs over the quartiles by scoring the categories according to the median (ln) hormone value for each quartile.